CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236
SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ('CERo' or the 'Company') an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells, announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark Office (USPTO), and one European patent application has been allowed by the European Patent Office, all of which significantly expand the Company's intellectual property portfolio.
The USPTO granted U.S. Patent No. 12,291,557, titled, 'CHIMERIC TIM4 RECEPTORS AND USES THEREOF' on May 6, 2025. The granted claims cover certain design aspects of CER-1236, the Company's lead compound. This patent provides composition of matter protection for a chimeric TIM4 receptor comprising a TIM4 binding domain and canonical T cell signaling domains.
Additionally, the European Patent Office has allowed European Patent Application No. 1882166.7 titled, 'CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE' on May 16, 2025. The allowed claims encompass a chimeric engulfment receptor comprising a TIM4 binding domain and TLR2 signaling domain. The allowance of this European patent application expands protection of additional design aspects of CER-1236, which have already been granted in the U.S., Japan, and China.
Finally, the USPTO granted U.S. Patent No. 12,303,551, titled, 'CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,' on May 20, 2025. This patent provides coverage for combination cellular immunotherapy compositions and methods of use for CER-1236. The patent covers combination of a chimeric engulfment receptor CD4+ T cell (CD4+ CER-T cell) with a chimeric antigen receptor CD8+ T cell (CD8+ CAR-T cell) or T cell receptor CD8+ T cell (CD8+ TCR-T cell), and their use to treat cancer. This type of combination therapy could be an exciting avenue to complement the CER-T cell technology with other powerful anti-cancer therapies. CERo's intellectual property portfolio now includes 9 total patent families with protection out to 2042 in the United States.
With these additional granted patents and allowed application, CER-1236 and its platform technology is supported by 18 total issued patents and allowed patent application internationally.
Chris Ehrlich, CERo Therapeutics CEO, commented, 'We continue to aggressively expand our intellectual property portfolio, as it ensures CERo's success in the market. These patents protect the core innovations of the CER-T technology that differentiate it from other cell therapies and demonstrate the true novelty of our design . We continue to seek a robust range of patents across multiple geographies that cover this technology in general, and CER-1236 in particular. The appreciation of the novelty of the CER-T technology by the patent offices validates the innovation and therapeutic potential of this approach, and we believe that we will continue to grow the portfolio. In the near term, we anticipate updates on our clinical trial progress in AML, and the announcement of initiating human trials to treat ovarian and non-small cell lung cancers.'
About CERo Therapeutics Holdings, Inc.
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies.
Forward-Looking Statements
This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo's management.
Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo's filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:Chris EhrlichChief Executive Officerchris@cero.bio
Investors:CORE IRinvestors@cero.bio
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Stifel Keeps Buy Rating on Compass Therapeutics (CMPX)
Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 10 Best Performing Penny Stocks So Far in 2025. On July 14, Stifel reiterated its 'Buy' rating for Compass Therapeutics, Inc. (NASDAQ:CMPX) with a price target of $11. This decision came after investor meetings with the company's management. According to the research firm, the extended timeline for overall survival event accrual in the Phase 2/3 COMPANION-002 trial is a good thing. The trial is testing paclitaxel with or without tovecimig in patients with second-line biliary tract cancer. A biopharmacist holding a magnifying glass up against a microscope lens, studying a biological sample. Compass Therapeutics, Inc. (NASDAQ:CMPX) now expects to share the topline data in the fourth quarter of 2025. This means patients will be followed up for more than 19 months on average. Stifel noted that this is important because in this disease, the overall survival of the control arm rarely goes beyond 6 months. Besides the COMPANION-002 trial, Stiefl analysts believe upcoming data disclosures for two other compounds in the second half of 2025 could potentially prove to be important catalysts for Compass Therapeutics, Inc. (NASDAQ:CMPX). These include Phase 1 dose-escalation data for CTX-8371, a PD-1xPD-L1 bispecific antibody, and preclinical data for CTX-10726, a PD-1xVEGF-A bispecific antibody. Compass Therapeutics, Inc. (NASDAQ:CMPX) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. The company focuses on the relationship between angiogenesis, the immune system, and tumor growth. While we acknowledge the potential of CMPX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
CytomX (CTMX) Shares Promising Early Results for CRC Drug Candidate
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the 10 Best Performing Penny Stocks So Far in 2025. On May 12, CytomX Therapeutics, Inc. (NASDAQ:CTMX) shared encouraging interim Phase 1 data for CX-2051, its EpCAM PROBODY ADC candidate, in advanced, late-line colorectal cancer (CRC). The findings were based on data collected as of April 7, 2025, from the ongoing CTMX-2051-101 Phase 1 study. A researcher in a lab coat observing a microscope, studying molecules in the companys antibody therapeutics. As part of this trial, 23 patients were treated with three different doses. These were the 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses. Out of these, 18 patients could be assessed, having had a minimum of one post-baseline tumor assessment as of the data cutoff. According to the report by CytomX Therapeutics, Inc. (NASDAQ:CTMX), CX-2051 was generally well-tolerated with manageable side effects, with no observed dose-limiting toxicities. CX-2051 is showing strong and durable anti-tumor activity in late-line metastatic CRC, which is a very hard tumor to treat. Sean McCarthy, D. Phil, CEO and chairman of CytomX Therapeutics, Inc. (NASDAQ:CTMX), noted that this is an area that has high unmet needs. Overall, CX-2051 has been generally safe, which highlights the potential of CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) special PROBODY masking technology. CytomX Therapeutics, Inc. (NASDAQ:CTMX) is a clinical-stage, oncology-focused biopharmaceutical company focused on developing masked biologics that conditionally activate in the tumor microenvironment. While we acknowledge the potential of CTMX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Why Palantir Is The 'AI All-Star' You Need To Watch
Palantir Technologies Inc. (NASDAQ:PLTR) has risen from the ashes of doubt to become one of the most talked-about names in the AI revolution. Calling it an 'AI All-Star,' Piper Sandler analyst Brent A. Bracelin sees this transformation as more than just a rebound, framing Palantir as a long-term winner in the evolving AI landscape. The analyst initiated coverage on the stock with an Overweight rating and a price forecast of $ highlights that Palantir has been closely followed for over five years, evolving from a highly sought-after late-stage private company to one that made its public debut via direct listing in September 2020. The analyst recalls the challenging phase in late 2022, when investor confidence in Palantir's ability to sustain 30%+ multi-year growth waned, pushing the stock to lows of around $6. Since then, however, the company has staged a significant comeback, what Bracelin refers to as a 'rise of the phoenix', and is now regarded as a standout player in the AI space due to its accelerating growth momentum. While the analyst acknowledges that Palantir's valuation is steep and the investment carries a high degree of risk, Bracelin points out that its unique combination of strong growth and expanding margins could support a $24 billion annual revenue run rate by calendar year 2032, as the company captures market share across two addressable markets worth over $1 trillion each. In Bracelin's view, Palantir is well-positioned to emerge as a long-term AI winner. However, given the stock's history of high volatility, including more than a dozen pullbacks in the 20–29% range, he advises a patient, opportunistic approach by buying on dips to build positions over time. Bracelin points out that recent data on unique visitor traffic across four prominent Defense Tech firms, Palantir, Anduril, Shield AI, and Axon, indicates that Palantir has seen its year-over-year visitor growth surpass triple digits for the first time in two years. While he acknowledges that rising web traffic doesn't necessarily translate directly into higher revenues, it does act as a useful proxy for gauging relative market interest compared to similar companies. Among the four companies reviewed, only Palantir and Anduril are currently exhibiting triple-digit annual growth in unique visitors, underscoring their growing prominence in the Defense Tech landscape. He also reflects on the distinctive and often unconventional trajectory that has defined Palantir's evolution, most notably, its decision to sue (and ultimately win against) the U.S. Army, a rare move for a defense-oriented startup. Bracelin emphasizes that Palantir's journey to achieving a ~$4 billion revenue run-rate, coupled with free cash flow margins exceeding 40%, has spanned over two decades and has been marked by a unique blend of culture, leadership style, and strategic decisions. Price Action: PLTR shares are trading higher by 2.55% to $158.78 at last check Friday. Read Next:Image via Shutterstock Latest Ratings for PLTR Date Firm Action From To Mar 2022 Piper Sandler Initiates Coverage On Overweight Mar 2022 Morgan Stanley Upgrades Underweight Equal-Weight Feb 2022 Citigroup Maintains Sell View More Analyst Ratings for PLTR View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? PALANTIR TECHNOLOGIES (PLTR): Free Stock Analysis Report This article Why Palantir Is The 'AI All-Star' You Need To Watch originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio